Tecan outlines long-term strategy, shares on SIX Swiss Exchange under review

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 13:48.

Tecan Group AG (CH0012100191) continues to position itself as a specialist in laboratory automation and diagnostics with a broad global footprint. The Swiss company is listed on SIX Swiss Exchange, giving investors access via one of Europe’s key life sciences hubs.

How Tecan earns its revenue

Tecan reports its business in two main divisions: Life Sciences and Partnering. The Life Sciences business focuses on standardized instruments and reagents, while Partnering develops customized solutions and OEM platforms for diagnostics companies. Tecan investor relations overview

In its 2023 annual report, Tecan highlighted that Life Sciences accounted for a significant share of group sales, driven by demand for automated liquid handling and microplate readers. Partnering revenues reflected long-standing relationships with diagnostics and pharma customers across Europe, North America and Asia. 2023 annual report

Long-term growth drivers in lab automation

The company points to increasing automation in research and diagnostics laboratories as a structural growth driver. Higher assay throughput, reproducibility requirements and staffing constraints at labs support demand for robotic platforms and integrated workflows. Reuters commentary on lab automation

Tecan has emphasized recurring revenues from consumables and services linked to installed instruments as a stabilizing factor in its model. Service contracts, calibration, and application support strengthen customer relationships and underpin visibility in multi-year revenue streams. 2023 annual report

Sector peers in laboratory equipment

In the listed laboratory equipment space, peers include companies such as Bio-Techne and larger diversified groups like Thermo Fisher Scientific. These firms also serve pharmaceutical, biotech and diagnostics customers with tools and reagents. Reuters sector overview

Compared with broader diversified industrials, Tecan’s focus remains firmly in laboratory instrumentation and workflow solutions. This specialization can help the company respond more quickly to changes in research methods and diagnostics protocols than more diversified conglomerates. Tecan investor relations overview

The products behind the stock

Tecan is known for modular liquid handling platforms such as the Fluent and Freedom EVO series, which automate pipetting and sample preparation across genomics, proteomics and clinical diagnostics laboratories. These systems are often combined with readers and software for complete workflows. Tecan Fluent platform

Where the Tecan shares trade today

The Tecan Group AG shares (CH0012100191) last traded on SIX Swiss Exchange at 176.50 Swiss francs as of 2026-06-26, 16:43, according to recent price data.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All data are based on sources believed to be reliable but may change without notice.